Articles

Results are in for this year's award recipients! 

AAO, AAOF announce 2022 award recipients

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

NIH-funded clinical trial results support “step therapy” for DME treatment

Glaucoma search study finds online medical resources lack readability.

Making the case for greater health care literacy 

Videos

Optometry Times' editor Kassi Jackson speaks with Lauretta Justin, OD, founder of Optometry Divas, and Alexis Meyer, a third year student at UC Berkeley School of Optometry and recipient of Optometry Divas' second annual CEO of You scholarship.

Scholarship offers opportunity, empowerment to second annual recipient

Bradley Middaugh, OD, graduated from Wake Forest University and earned his doctorate at the University of Alabama at Birmingham. He has been in private practice since 1988 and founded The Fort Myers Eye Center in 1993. In 2020, he joined the Center for Sight team to offer his patients direct access to some of the finest cataract, LASIK, glaucoma, cornea, retina, and oculo-plastics specialists in Southwest Florida.

Dedicating part of your practice to a pediatric patient base allows you to have fun, as well as continue growing your practice.

Why you should consider adding pediatrics to your practice

Clinical trials evaluate corneal staining changes in patients.

Impact of drug-eluting contact lenses on ocular surface health 

Published in Optometry & Visual Sciences, the findings are based on an independent survey featuring feedback from over 500 US eye care professionals. 

Report: ortho-K expected to surge over next 2 years

Optic relief: Cramming for the exam

Studies conducted with Orbis International conclude positive mental health and academic improvements of children provided appropriate eye care and glasses, filling important research gaps and providing essential guidance for future interventions and research.

Impact of vision impairment on children’s mental health

IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.


AAO, AAOF announce 2022 award recipients

NIH-funded clinical trial results support “step therapy” for DME treatment

Making the case for greater health care literacy

SAP Content